WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. .

马萨诸塞州沃尔瑟姆，2026年10月6日（环球电讯社）——专注于生物工艺技术领导地位的生命科学公司Repligen Corporation（纳斯达克股票代码：RGEN，简称“Repligen”或“公司”）今日宣布，已完成此前宣布的对BioLife Solutions, Inc.（纳斯达克股票代码：BLFS，简称“BioLife”）的收购。BioLife是细胞和基因治疗市场领先的细胞处理工具和服务开发商及供应商。

“We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue.

“我们很高兴欢迎 BioLife 团队成员加入 Repligen，”Repligen 总裁兼首席执行官 Olivier Loeillot 表示。“BioLife 高度差异化的产品组合扩大了我们在快速增长的细胞治疗市场的影响力，并为我们增添了一项根基深厚、高利润率的耗材业务，带来诱人的经常性收入。”

Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.”.

携手合作，使我们能够更有力地支持客户应对细胞治疗工作流程中的关键阶段，并推动下一代疗法的开发与商业化。在过去几个月里，我们的团队密切协作，制定了周密的整合计划。我们对此次合并的战略逻辑以及将为患者、客户和股东创造的价值感到更加振奋。

BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen’s existing offering in this market. BioLife’s differentiated biopreservation media portfolio, led by CryoStor

BioLife 的产品深度融入细胞治疗工作流程，并与 Repligen 在该市场的现有产品高度互补。BioLife 以 CryoStor 为主导的差异化生物保存培养基产品组合

®

®

, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.

，支持18种已获商业批准的疗法，并涵盖美国大多数由企业赞助的细胞疗法临床试验。作为一个统一的商业团队，BioLife将受益于Repligen更广泛的全球覆盖范围（包括亚太地区），而Repligen则将受益于BioLife与客户之间建立的信赖关系。

.

。

In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock.

在此次交易中，BioLife 的股东每股获得了 11.25 美元的现金以及 0.1442 股 Repligen 普通股，其中零碎股份的 Repligen 普通股以现金代替。

Repligen intends to provide additional detail regarding the transaction’s expected impact on Repligen’s 2026 financial outlook in the upcoming third quarter 2026 earnings call.

Repligen 计划在即将举行的2026年第三季度财报电话会议上，提供有关此次交易对公司2026年财务展望预期影响的更多细节。

Advisors

顾问

Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife.

佩雷拉·温伯格合伙人有限合伙企业（Perella Weinberg Partners LP）和高盛有限责任公司（Goldman Sachs & Co. LLC）担任雷普里金公司（Repligen）的财务顾问，古德温·普罗克特律师事务所（Goodwin Procter LLP）担任其法律顾问。森维尤合伙人有限责任公司（Centerview Partners, LLC）担任百奥生命公司（BioLife）的财务顾问，K&L Gates 律师事务所（K&L Gates LLP）担任其法律顾问。

About Repligen Corporation

关于雷普利根公司

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are

Repligen Corporation 是一家全球性的生命科学公司，致力于开发并商业化高度创新的生物工艺技术与系统，以提升生物药物制造过程的效率。我们是

“inspiring advances in bioprocessing”

“生物加工领域的鼓舞人心的进展”

for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

我们服务的客户主要是全球生物制药药物开发商和合同研发与生产组织（CDMO）。我们的重点领域包括过滤与流体管理、色谱、过程分析以及蛋白质。公司总部位于马萨诸塞州沃尔瑟姆，大部分生产基地位于美国，并在爱沙尼亚、德国、爱尔兰、荷兰和瑞典设有其他关键基地。

For more information about the company see our website at .

有关公司的更多信息，请访问我们的网站。

www.repligen.com

www.repligen.com

, and follow us on

，并在 上关注我们

LinkedIn

领英

.

。

Forward-Looking Statements

前瞻性陈述

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen’s ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen’s performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader.

本新闻稿可能包含联邦证券法定义下的前瞻性陈述。提醒投资者注意，本新闻稿中并非严格基于历史事实的陈述，包括但不限于以下陈述：关于交易预期收益及Repligen实现此类收益的能力；交易对Repligen的预期财务影响；交易后Repligen业绩的预期；以及对细胞治疗行业（包括其增长）的信念和预期，以及BioLife作为高度差异化的细胞处理工具领导者的地位。

Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission.

“相信”、“预期”、“可能”、“将”、“应当”、“寻求”或“可以”等词语及其变体以及类似表述，旨在识别此类前瞻性陈述。此类前瞻性陈述受多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与预期存在重大差异，包括我们在向美国证券交易委员会提交的文件中不时讨论的风险。

We expressly disclaim any responsibility to update any forward-looking statements, except as required by law. .

除法律要求外，我们明确声明不对任何前瞻性陈述承担更新责任。

Repligen Contact:

Repligen 联系人：

Jacob Johnson

雅各布·约翰逊

VP, Investor Relations

投资者关系副总裁

781-419-0204

781-419-0204

investors@repligen.com

investors@repligen.com